Reimbursement

Jesse C. Dresser, Esq explains how DIR fees affect specialty pharmacists at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains a recent piece of PBM legislation from North Dakota and its implications for specialty pharmacy at the NASP Annual Meeting in Washington, DC.

Jesse C. Dresser, Esq explains the current climate of PBM reform at the NASP Annual Meeting in Washington, DC.

Care planning can increase pharmacy profits through efficiencies and through new revenue from payers that value what pharmacists do for patients, if they see the documentation of what has been done.

Making medication synchronization a core tenet of a pharmacy’s business can lead to success.

Utilizing many of the skills learned in pharmacy school could help to personalize care and enhance medication delivery for patients, potentially leading to reductions in adverse drug events and health care costs,

Reform of pharmacy benefit management (PBM) practices has been an issue under much scrutiny due to a belief these entities play a significant role in exacerbating high drug costs.

As pharmacists continue to provide more direct patient-centric services, the case for technicians to take on managing pharmacy inventory becomes more reasonable.

In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new report found that widely used prescription drugs increased by an average of 4.2% in 2017, double the general inflation rate of 2.1%.

As the cost of treating the disease has risen, so too have the direct medical care expenses that patients pay out of pocket, as commercial insurers increasingly shift the burden of paying for treatment to patients through higher premiums, deductibles, and co-pays.

David Pope, PharmD, CDE, and chief innovation officer of OmniSYS, and John King, CEO of OmniSYS, discuss some opportunities to leverage cash prescriptions to drive revenue in the pharmacy.

Community Pharmacy Consultant Bruce Kneeland and Theresa Dickinson, RPh, owner of Melrose Pharmacy in Phoenix, AZ, discusses direct payment options for payers and patients.

John King, CEO, and David Pope, Chief Innovation Officer, of OmniSYS, discuss how they're tackling reimbursement issues for pharmacies.

These techs are key players in navigating the complexities of the compliance requirements and training staff.

In 2018, the drugs generated $293 billion in savings, based on a recent AAM report.

When a pharmacist and a pharmacy assistant are indicted on charges of defrauding a government health insurance program and make motions with the relevant federal court to overturn the charges, should they prevail, heading off a trial, or should the matter proceed to trial?

The American Society of Health-System Pharmacists (ASHP) has released a statement opposing the Centers for Medicare and Medicaid Services’ (CMS) proposed cuts to reimbursement for drug purchased through the 340B Drug Pricing Program.

Eyad Farah, Vice President and General Manager, Health Mart Atlas discusses what the company is doing to lower DIR fees for Health Mart pharmacies.

That is the message that pharmacy leaders must send to payers and pharmacy benefit managers.

Direct and indirect remuneration (DIR) fees are imposed by pharmacy benefit managers (PBMs) on pharmacy providers after a drug claim has already been submitted, adjudicated, and even paid out to a pharmacy.

Loren Kirk, director of Stakeholder Engagement for the Pharmacy Quality Alliance, speaks to Pharmacy Times on the findings of the Pharmacy-Provided Care Action Guide Report, during the Pharmacy Quality Alliance Annual Meeting.

The nature of pharmacy reimbursement in changing, shifting from the standard fee-for-service, 'fill-and-bill' model to a patient-centric, value-based system. However, the transition between these 2 means of revenue is often confusing and frustrating for independent pharmacists.

Bruce Kneeland, community pharmacy consultant, discusses enrolling patients in patient assistance programs, in an interview with Pharmacy Times.

Nimesh Jhaveri, President of Health Mart, discusses how local pharmacies can grow their patient base.

To date, the Ohio audit is the first comprehensive review of PBM practices and incorporated 39 million drug transactions, the authors said.

Bruce Kneeland, community pharmacy consultant, discusses point-of-care testing as a form of cash-paid services, in an interview with Pharmacy Times.

Once the basics of vaccine billing are understood, pharmacists can easily take advantage of this growth opportunity.

Hidden direct and indirect remuneration fees survive another round after announcement of final rule.